Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence

The Latest

• 

  Abbott receives CE mark for dual glucose-ketone sensor

  Abbott’s first dual-analyte sensor comes as competitors are working to develop their own versions of the technology.

  Diabetes

• 

  AI in medtech is booming. Track new devices here.

  The Food and Drug Administration has authorized more medical devices that incorporate artificial intelligence. Keep track of the latest developments in this database.

  Updated May 27, 2026

  AI

• 

  Insulet recalls 7M patch pumps due to leak risk

  The recall is Insulet’s second this year related to tears in the device tubing. So far, 24 serious adverse events have been reported.

  Recalls

• 

  J&J’s DePuy Synthes inks deal to buy orthopedic surgery tech

  The acquisition is the latest in a series of agreements between DePuy Synthes and organizations associated with entrepreneur Stéphane Lavallée.

  M&A

• 

  Dexcom warns of scrapped glucose sensors being resold

  Dexcom has identified two lots of G7 sensors that have been stolen, sold and used by customers.

  Updated May 27, 2026

  Recalls

• 

  Olympus expands in cancer tech with $270M buy of BioProtect

  BioProtect’s balloon spacer device separates the prostate from other structures during cancer radiation.

  M&A

• 

  J&J corrects Impella controller over issue linked to 2 injuries, 1 death

  The controller can stop for about 35 seconds, during which time the patient is unsupported by the heart pump.

  FDA

• 

  Beta Bionics to launch its first insulin patch pump to compete with Insulet

  The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.

  Diabetes

• 

  Ōura files for IPO amid healthcare push

  The smart ring maker’s filing follows a recent $900 million fundraise and comes amid plans to develop more health features for the device.

  Digital Health

• 

  Medtronic to create European software hub in Ireland

  The investment in cardiac digital health will add 85 jobs initially, with more growth expected over the next three years.

  Cardiac

• 

  Intuitive readies 100 updates and improvements for da Vinci 5

  Some updates to Intuitive’s surgical robot aim to improve communication between remote and on-site physicians to expand education opportunities.

  Medical Devices

• 

  Sentante lands Europe’s CE mark for endovascular robot

  The Lithuania-based robotic surgery company is advancing a remote stroke system that was accepted into the FDA’s total product life cycle advisory program earlier this year.

  Medical Devices

• 

  Medtronic to buy SPR Therapeutics for about $650M

  Medtronic would gain a treatment for chronic pain management in its third major acquisition this year.

  M&A

• 

  Stryker’s chief accounting officer to retire

  William Berry Jr. will retire in September, with Corporate Controller Emily Baculik stepping into the role.

  Earnings

• 

  Guardant wins FDA approval for updated liquid biopsy

  The company could secure a higher price for the new test than for its older, narrower product, Wall Street analysts said.

  FDA

• 

  Medtronic data back renal denervation in the long term

  Analyses presented at EuroPCR assessed Medtronic’s Symplicity blood pressure procedure in patient groups with severe hypertension and who had prior cardiovascular events.

  Cardiac

• 

  Endologix buys clot removal system from Surmodics

  Endologix will market the system to vascular interventionists who use its other devices to treat peripheral artery disease and abdominal aortic aneurysms.

  M&A

• 

  Top medtech executive moves in 2026

  Integra LifeSciences has reappointed Stuart Essig as CEO, and Edwards Lifesciences and BD named new CFOs. Read MedTech Dive’s roundup for all the details.

  Updated May 20, 2026

  M&A

• 

  Boston Scientific posts positive data for coronary IVL catheter

  With the study results, Boston Scientific plans a regulatory submission for the intravascular lithotripsy treatment for patients with severely calcified coronary artery disease.

  Cardiac

• 

  Medtronic, BD name new leaders

  Kweli Thompson will be promoted to head of Medtronic’s neuroscience portfolio, and Peter Menziuso will join BD’s interventional business. 

  Medical Devices

• 

  Artivion closes Endospan buyout to acquire recently approved heart device

  Artivion is targeting a $150 million annual U.S. market for the Nexus Aortic Arch System.

  M&A

• 

  Boston Scientific buys $1.5B stake in TAVR developer MiRus

  The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.

  M&A

• 

  Natera wins FDA approval for companion diagnostic

  The test will enable physicians to assess if post-surgery cancer patients need to receive treatment to minimize the risk of recurrence.

  FDA

• 

  Embecta closes Owen Mumford acquisition for up to $201M

  Embecta bought the company, which has an auto-injector platform, to expand outside of diabetes care.

  M&A

• 

  Dexcom to add 2 board directors with activist investor Elliott

  CEO Jake Leach also discussed the company’s plans for its G8 glucose sensor, dual-analyte sensing and Medicare coverage at an investor day.

  Diabetes

More stories